In the overall survival (OS) analysis (Fig. 2A and D), disease-specific survival (DSS) analysis (Fig. 2B), progression-free interval (PFI) analysis (Fig. 2C), recurrence-free survival (RFS) analysis (Fig. 2E), and distant metastasis-free survival (DMFS) analysis (Fig. 2F), high expression of CCDC69 was always a protective factor in breast cancer with statistical significance. Here, CCDC69 is linked to breast carcinoma.